Skip to main content
TipRanks
Go Ultimate75% OFF

Phio Pharmaceuticals (PHIO) AI Stock Analysis

668 Followers
PHIO

Phio Pharmaceuticals

(NASDAQ:PHIO)

Select Model
Rating:43Neutral
Price Target:$0.77â–²(2.66% Upside)
Action:reiterated
Date:11/06/26

Overall score is held down primarily by weak financial performance (no revenue, widening losses, and increasing cash burn implying continued financing risk) and bearish technicals (price below key moving averages with negative MACD). Positive pipeline milestones provide some offset, but do not outweigh the current financial and trend headwinds.

Positive Factors
Manufacturing readinessThe completed commercial-scale cGMP batch demonstrates progress beyond early laboratory development and supports supply for the planned Phase 2b trial. This milestone reduces manufacturing execution risk, strengthens operational readiness, and improves the program’s ability to advance on its stated clinical timeline.
Negative Factors
Pre-revenue modelPHIO has no commercial product revenue to offset research and development spending, so financial performance remains tied to external funding and clinical progress. Without a revenue base, near-term earnings improvement is difficult to establish and operating losses can persist while candidates are tested.

Phio Pharmaceuticals (PHIO) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%30%40%PHIO-39.84%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$9.21M
Dividend Yield
―
Average Volume (3M)
119.52K
Price to Earnings (P/E)
-0.6
Beta (1Y)
2.12
Revenue Growth
―
EPS Growth
43.66%
Country
US
Employees
6
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Phio Pharmaceuticals Business Overview & Revenue Model

Company Description

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center...

How the Company Makes Money

Phio Pharmaceuticals is a clinical-stage company and does not have a product portfolio marketed for commercial sale; therefore, recurring product revenue from drug sales is null. Its ability to generate revenue, when it occurs, is typically tied to n...

Phio Pharmaceuticals Financial Statement Overview

Summary

Financial performance is weak: the company is pre-revenue ($0 revenue across periods), losses have widened in TTM (net loss about -$14.7M vs -$8.7M in 2025), and cash burn increased (operating cash flow about -$12.4M TTM vs -$8.0M in 2025). Low debt reduces leverage risk, but shrinking/volatile equity and persistent negative free cash flow point to ongoing financing dependence.

Income Statement

12Very Negative

Balance Sheet

48Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit-1.48M-4.62M-3.64M-6.33M-7.01M-8.89M
EBITDA-15.06M-8.70M-7.12M-10.64M-11.29M-13.21M
Net Income-14.67M-8.70M-7.15M-10.83M-11.48M-13.29M
Balance Sheet
Total Assets11.32M21.49M5.74M9.36M12.81M25.17M
Cash, Cash Equivalents and Short-Term Investments10.61M21.03M5.38M8.49M11.78M24.06M
Total Debt00035.00K170.00K295.00K
Total Liabilities2.70M1.34M1.01M1.63M1.97M3.24M
Stockholders Equity8.62M20.15M4.72M7.73M10.84M21.93M
Cash Flow
Free Cash Flow-12.40M-7.99M-7.11M-10.75M-12.25M-11.91M
Operating Cash Flow-12.40M-7.98M-7.11M-10.75M-12.13M-11.86M
Investing Cash Flow3,000-12.00K8,000-5,000-121.00K-51.00K
Financing Cash Flow12.30M23.64M4.00M7.41M-26.00K21.72M

Phio Pharmaceuticals Technical Analysis

Technical Analysis SentimentNegative
Last Price0.75

Price Trends

50DMA0.93Negative
100DMA1.00Negative
200DMA1.07Negative

Market Momentum

MACD-0.04Positive
RSI30.54Neutral
STOCH21.22Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHIO, the sentiment is Negative. The current price of 0.75 is below the 20-day moving average (MA) of 0.85, below the 50-day MA of 0.93, and below the 200-day MA of 1.07, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 30.54 is Neutral, neither overbought nor oversold. The STOCH value of 21.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PHIO.

Phio Pharmaceuticals Risk Analysis

Phio Pharmaceuticals disclosed 23 risk factors in its most recent earnings report. Phio Pharmaceuticals reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

2 New Risks
1.We may not be able to regain compliance with the continued listing requirements of The Nasdaq Capital Market.Q4, 2023
2.Our business and operations would suffer in the event of computer system failures, cyberattacks or a deficiency in our cybersecurity.Q4, 2023

Phio Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

PHIO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
PASGPASG50Neutral$13.29M-0.38-377.94%――28.49%
PHIOPHIO43Neutral$8.99M-0.59-101.48%――43.66%
XCURXCUR42Neutral$7.00M-0.83-237.91%――23.05%
SNTISNTI39Underperform$4.24M-0.08-1539.97%――80.28%
INABINAB38Underperform$8.82M-0.70-93.66%――81.16%
KALAKALA28Underperform$2.47M-0.00-222.32%――78.25%

* Healthcare Sector Average

Performance Comparison

-100%-50%0%50%100%PHIOKALAXCURPASGINABSNTIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PHIO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PHIOPhio Pharmaceuticals0.75-0.52-40.79%
KALAKala Bio, Inc.3.83-1029.37-99.63%
XCURExicure1.07-2.66-71.31%
PASGPassage Bio, Inc.4.13-4.39-51.53%
INABIn8bio, Inc.0.82-0.82-50.24%
SNTISenti Biosciences, Inc.0.14-1.57-92.05%

Phio Pharmaceuticals Corporate Events

Business Operations and StrategyProduct-Related Announcements

Phio Pharmaceuticals Advances PH-762 With Commercial-Scale cGMP Batch

Positive
Oct 13, 2026

On October 13, 2026, Phio Pharmaceuticals announced it had successfully completed and released its first commercial-scale cGMP batch of PH-762 drug substance, manufactured under current Good Manufacturing Practice regulations and ICH Q7 guidelines. T...

Business Operations and StrategyExecutive/Board ChangesShareholder Meetings

Phio Pharmaceuticals Expands Equity Incentive Pool at Meeting

Neutral
Sep 28, 2026

Phio Pharmaceuticals held its 2026 Annual Meeting of Stockholders via live webcast on September 28, 2026, where shareholders approved an amendment to its 2020 Long Term Incentive Plan, increasing the number of shares available for issuance by 1,500,0...

Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance

Phio Advances PH-762 Toward Phase 2b Skin Cancer Trial

Positive
Sep 14, 2026

On September 14, 2026, Phio Pharmaceuticals announced a key development milestone for its lead candidate PH-762 following formal completion of a Phase 1b trial in skin cancers. The company submitted a meeting request and comprehensive briefing packag...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026